#特殊劑型：不建議磨粉、管灌藥品

Parkinson's disease (PD)

Pramipexole is a non-ergot dopamine agonist and binds with high selectivity and specificity to the dopamine D2 receptors and has a preferential affinity to D3 receptors; it has full intrinsic activity.

Bioavailability: ＞90 % , protein binding: very low (< 20 %); the volume of distribution is large (400 L). Renal excretion of unchanged pramipexole is the major route of elimination and accounts for about 80% of dose. Elimination half-life: 8-12 hr. Pramipexole is not removed by hemodialysis.

Hypersensitivity to pramipexole products

C

Avoided.

abnormal behaviour, abnormal dreams, confusion, constipation, delusion, dizziness, dyskinesias, fatigue, hallucinations, headache, hyperkinesia, hypotension, increased eating (binge eating, hyperphagia), insomnia, libido disorders, nausea, peripheral oedema, paranoia, pathological gambling, somnolence, weight increase, and sudden onset of sleep

1. Treatment of PD: initial, 0.375 mg ORALLY once daily, slow titration every 5 to 7 days, first to 0.75 mg/day and then in 0.75-mg increments; MAX, 4.5 mg/day; evaluate response at a minimal interval of 5 days or longer after each dose increment.
2. Discontinuation of therapy: Do not discontinue abruptly; the manufacturer of the IR and ER formulations recommends reducing dose by 0.75 mg/day until daily dose is 0.75 mg, then reducing by 0.375 mg/day thereafter.<20231122>